Journal
NATURE COMMUNICATIONS
Volume 5, Issue -, Pages -Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/ncomms3977
Keywords
-
Categories
Funding
- Ovarian Cancer Research Program CDMRP [W81XWH-11-1-0609]
- Department of Defense
- Ovarian Cancer Research Fund Liz Tilberis Scholar
- Young Scientist Cancer Research Fund at Mount Sinai School of Medicine
- Athymic Animal and Xenograft Core Facility of the Case Comprehensive Cancer Center [P30CA043703]
- Harrington Discovery Institute
- Pardee-Gerstacker Professor in Cancer Research
- Nerina and Mario Mattioli Foundation
- ACTO
- Italian Association for Cancer Research [IG11673]
Ask authors/readers for more resources
Ovarian cancer is a leading cause of cancer deaths among women. Effective targets to treat advanced epithelial ovarian cancer (EOC) and biomarkers to predict treatment response are still lacking because of the complexity of pathways involved in ovarian cancer progression. Here we show that miR-181a promotes TGF-beta-mediated epithelial-to-mesenchymal transition via repression of its functional target, Smad7. miR-181a and phosphorylated Smad2 are enriched in recurrent compared with matched-primary ovarian tumours and their expression is associated with shorter time to recurrence and poor outcome in patients with EOC. Furthermore, ectopic expression of miR-181a results in increased cellular survival, migration, invasion, drug resistance and in vivo tumour burden and dissemination. In contrast, miR-181a inhibition via decoy vector suppression and Smad7 re-expression results in significant reversion of these phenotypes. Combined, our findings highlight an unappreciated role for miR-181a, Smad7, and the TGF-beta signalling pathway in high-grade serous ovarian cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available